JP2013510883A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510883A5
JP2013510883A5 JP2012539063A JP2012539063A JP2013510883A5 JP 2013510883 A5 JP2013510883 A5 JP 2013510883A5 JP 2012539063 A JP2012539063 A JP 2012539063A JP 2012539063 A JP2012539063 A JP 2012539063A JP 2013510883 A5 JP2013510883 A5 JP 2013510883A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
moiety
formula
membered saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539063A
Other languages
English (en)
Japanese (ja)
Other versions
JP5988379B2 (ja
JP2013510883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056757 external-priority patent/WO2011060389A1/en
Publication of JP2013510883A publication Critical patent/JP2013510883A/ja
Publication of JP2013510883A5 publication Critical patent/JP2013510883A5/ja
Application granted granted Critical
Publication of JP5988379B2 publication Critical patent/JP5988379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539063A 2009-11-13 2010-11-15 スフィンゴシン−1−リン酸受容体変調因子および不斉合成方法 Active JP5988379B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26128209P 2009-11-13 2009-11-13
US61/261,282 2009-11-13
US26247409P 2009-11-18 2009-11-18
US61/262,474 2009-11-18
PCT/US2010/056757 WO2011060389A1 (en) 2009-11-13 2010-11-15 Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Publications (3)

Publication Number Publication Date
JP2013510883A JP2013510883A (ja) 2013-03-28
JP2013510883A5 true JP2013510883A5 (cg-RX-API-DMAC7.html) 2014-01-09
JP5988379B2 JP5988379B2 (ja) 2016-09-07

Family

ID=43992104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539063A Active JP5988379B2 (ja) 2009-11-13 2010-11-15 スフィンゴシン−1−リン酸受容体変調因子および不斉合成方法

Country Status (25)

Country Link
US (3) US8357706B2 (cg-RX-API-DMAC7.html)
EP (1) EP2498611B1 (cg-RX-API-DMAC7.html)
JP (1) JP5988379B2 (cg-RX-API-DMAC7.html)
KR (1) KR101781233B1 (cg-RX-API-DMAC7.html)
CN (1) CN102724880B (cg-RX-API-DMAC7.html)
AU (1) AU2010320041B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012011430A8 (cg-RX-API-DMAC7.html)
CA (1) CA2780433C (cg-RX-API-DMAC7.html)
CY (1) CY1120427T1 (cg-RX-API-DMAC7.html)
DK (1) DK2498611T3 (cg-RX-API-DMAC7.html)
EA (1) EA023183B1 (cg-RX-API-DMAC7.html)
ES (1) ES2665461T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180527T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036391T2 (cg-RX-API-DMAC7.html)
IL (1) IL219690B (cg-RX-API-DMAC7.html)
LT (1) LT2498611T (cg-RX-API-DMAC7.html)
MX (1) MX2012005562A (cg-RX-API-DMAC7.html)
MY (1) MY160907A (cg-RX-API-DMAC7.html)
NZ (1) NZ599913A (cg-RX-API-DMAC7.html)
PH (1) PH12012500938A1 (cg-RX-API-DMAC7.html)
PL (1) PL2498611T3 (cg-RX-API-DMAC7.html)
PT (1) PT2498611T (cg-RX-API-DMAC7.html)
RS (1) RS57070B1 (cg-RX-API-DMAC7.html)
SI (1) SI2498611T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011060389A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57070B1 (sr) 2009-11-13 2018-06-29 Celgene Int Ii Sarl Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza
MY161854A (en) * 2009-11-13 2017-05-15 Receptos Inc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
ES2758841T3 (es) * 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
CN103251950B (zh) * 2012-02-16 2018-10-02 中国人民解放军军事科学院军事医学研究院辐射医学研究所 S1p受体调节剂防治肠型放射病及放射性肠炎的用途
MY170491A (en) * 2012-11-16 2019-08-08 Hoffmann La Roche Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters
DK2958913T3 (en) 2013-02-20 2018-11-05 Lg Chemical Ltd SPHINGOSIN-1 PHOSPHATRECEPTOR AGONISTS, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS AN ACTIVE AGENT
EP3062792A1 (en) * 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
SMT202300062T1 (it) 2015-11-13 2023-03-17 Oppilan Pharma Ltd Composti eterociclici per il trattamento di malattie
AU2016378650B2 (en) * 2015-12-22 2020-12-24 AbbVie Deutschland GmbH & Co. KG Fused (hetero)cyclic compounds as S1P modulators
EP3448519A4 (en) * 2016-04-29 2020-01-22 Board Of Regents, The University Of Texas System SIGMA RECEIVER BINDERS
BR112019001153A2 (pt) * 2016-07-22 2019-04-30 Shijiazhuang Sagacity New Drug Development Co., Ltd. agonista s1p1 e aplicação do mesmo
CN106749213B (zh) * 2016-11-25 2019-07-02 济南大学 一种具有1,2,4-恶二唑结构的吲哚衍生物及制备方法和在制备抗菌药物中的应用
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
CN110256288A (zh) * 2019-05-13 2019-09-20 苏州山青竹生物医药有限公司 一种制备(s)-1-氨基-2,3-二氢-1h-茚-4-甲腈的方法
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
JP2023509698A (ja) * 2020-01-06 2023-03-09 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連した状態の処置方法
US20230055568A1 (en) 2020-02-06 2023-02-23 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome
EP4116295A4 (en) * 2020-03-04 2023-08-02 Helioeast Pharmaceutical Co., Ltd. TRICYCLIC COMPOUNDS AND THEIR USE
CN121194965A (zh) 2023-05-31 2025-12-23 奎米卡新特缇卡股份有限公司 盐酸奥扎莫德的无定形形式和晶型

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
AU1886892A (en) 1991-04-12 1992-11-17 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en) * 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
NZ505599A (en) 1998-01-23 2003-06-30 Sankyo Co Morpholino alkyl substituted spiropiperidine derivatives useful as tachykinin receptor antagonists
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
CA2509218C (en) 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
EP3889142B1 (en) * 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
JP2007528872A (ja) * 2003-10-01 2007-10-18 メルク エンド カムパニー インコーポレーテッド S1p受容体アゴニストとしての3,5−アリール置換、ヘテロアリール置換またはシクロアルキル置換された1,2,4−オキサジアゾール化合物
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
CA2600008A1 (en) 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
EP1963509A4 (en) 2005-12-21 2009-07-29 Joseph Gabriele CATECHOLAMINE-REGULATED PROTEIN
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
KR20090095648A (ko) 2006-12-15 2009-09-09 아보트 러보러터리즈 신규한 옥사디아졸 화합물
WO2008106204A1 (en) 2007-02-28 2008-09-04 Rib-X-Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
US20090298894A1 (en) 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
MY156381A (en) * 2008-05-14 2016-02-15 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
EA025672B1 (ru) 2009-11-13 2017-01-30 Рецептос Ллк Селективные гетероциклические модуляторы рецептора сфингозин-1-фосфата
RS57070B1 (sr) 2009-11-13 2018-06-29 Celgene Int Ii Sarl Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza
MY161854A (en) 2009-11-13 2017-05-15 Receptos Inc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症

Similar Documents

Publication Publication Date Title
JP2013510883A5 (cg-RX-API-DMAC7.html)
JP2013510884A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2018515495A5 (cg-RX-API-DMAC7.html)
JP2009543860A5 (cg-RX-API-DMAC7.html)
JP2019520416A5 (cg-RX-API-DMAC7.html)
JP2014520809A5 (cg-RX-API-DMAC7.html)
JP6261011B2 (ja) 眼疾患処置薬
JP2011523412A5 (cg-RX-API-DMAC7.html)
RU2010143857A (ru) Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибриторов parp и ингибиторов полимеризации тубулина
JP2019501133A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2015505296A5 (cg-RX-API-DMAC7.html)
JP2014500295A5 (cg-RX-API-DMAC7.html)
JP2016503009A5 (cg-RX-API-DMAC7.html)
JP2009538910A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
CA2679198A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2011509301A5 (cg-RX-API-DMAC7.html)
JP2010527984A5 (cg-RX-API-DMAC7.html)
JP2007505931A5 (cg-RX-API-DMAC7.html)
JP2014517836A5 (cg-RX-API-DMAC7.html)
JP2011509302A5 (cg-RX-API-DMAC7.html)
JP2011517697A5 (cg-RX-API-DMAC7.html)
JP2010527985A5 (cg-RX-API-DMAC7.html)